Flutter was not as effective in maintaining pulmonary function in this group of patients with CF compared with PEP and was more costly because of the increased number of hospitalizations and antibiotic use.
http://www.ncbi.nlm.nih.gov/pubmed/11391327?dopt=AbstractPlus
The results of this study favour PEP and do not support the use of HFCWO as the primary form of AC in patients with CF.
http://www.ncbi.nlm.nih.gov/pubmed/23407019?dopt=AbstractPlus
No comments:
Post a Comment